Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Zhendong Chen"'
Autor:
Huiping Li, Yan Huang, Zhendong Chen, Aiping Zeng, Helong Zhang, Yan Yu, Shihong Wei, Qingshan Li, Xiaojia Wang, Xiangcai Wang, Xiuwen Wang, Runxiang Yang, Xiumei Dai, Minghong Bi, Tao Sun, Qingyuan Zhang, Cuicui Han, Yujie Li, Xiaoyan Kang, Yaxin Liu, Li Zhang
Publikováno v:
BioDrugs. 37:259-269
Autor:
Zhendong Chen, Max Taubert, Chunli Chen, Charalambos Dokos, Uwe Fuhr, Thomas Weig, Michael Zoller, Suzette Heck, Konstantinos Dimitriadis, Nicole Terpolilli, Christina Kinast, Christina Scharf, Constantin Lier, Christoph Dorn, Uwe Liebchen
Publikováno v:
Antimicrobial Agents and Chemotherapy.
Vancomycin is a commonly used antibacterial agent in patients with primary central nervous system (CNS) infection. This study aims to examine predictors of vancomycin penetration into cerebrospinal fluid (CSF) in patients with external ventricular dr
Publikováno v:
Pharmaceutical Research. 39:2147-2162
To clarify the mechanism of renal impairment leading to different degrees of increased plasma exposure to dipeptidyl peptidase 4 inhibitor vildagliptin and its major metabolite, M20.7.The 5/6 nephrectomized (5/6 Nx) rat model, to simulate chronic ren
Autor:
Xiaoyan Chen, Guangze Li, Xingxing Diao, Zitao Guo, Mengling Liu, Jinghua Yu, Qi Huang, Jian Meng, Yaru Xue, Dafang Zhong, Yuandong Zheng, Zhendong Chen, Yali Wu
Publikováno v:
Drug Metabolism and Disposition. 50:809-818
Excretion of [14C]HR011303-derived radioactivity showed significant species difference. Urine (81.50% of dose) was the main excretion route in healthy male subjects, whereas feces (87.16% of dose) was the main excretion route in rats. To further eluc
Autor:
Hongda Lin, Mengling Liu, Sheng Ma, Yan Zhan, Zhe Zhang, Yuandong Zheng, Guangze Li, Xingxing Diao, Dafang Zhong, Liyan Miao, Zhendong Chen, Hua Zhang
Publikováno v:
Drug Metabolism and Disposition. 50:798-808
HR011303, a promising selective URAT1 inhibitor, is currently being studied in a phase Ⅲ clinical trial in China for the treatment of hyperuricemia and gout. In the current study, the pharmacokinetics, mass balance, and metabolism of HR011303 were
Autor:
Song Chen, Zhendong Chen, Lixue Lu, Yunpeng Zhao, Ronghui Zhou, Qiong Xie, Yongzhi Shu, Jun Lin, Xufen Yu, Yonghui Wang
Publikováno v:
European Journal of Medicinal Chemistry. 255:115403
Publikováno v:
Current Drug Metabolism. 22:838-857
Metabolite identification plays a critical role in the phases during drug development. Drug metabolites can contribute to efficacy, toxicity, and drug-drug interaction. Thus, the correct identification of metabolites is essential to understand the be
Autor:
Jian-jun Zou, Yifan Zhang, Dafang Zhong, Xiao-fei Chen, Xin liang, Y. L. Zhu, Yan-mei Liu, Qian Chen, Hai-yan Liu, Jingying Jia, Zhendong Chen, Chen Yu, Yan Zhan
Publikováno v:
Clinical Therapeutics. 43:e264-e273
Purpose Henagliflozin is a highly selective and effective sodium glucose co-transporter (SGLT)-2 inhibitor developed for the treatment of patients with type 2 diabetes mellitus (T2DM). This study aimed to investigate the effects of meal intake on the
Publikováno v:
European journal of clinical pharmacology. 78(12)
A population pharmacokinetic (PPK) model for creatinine was successfully developed using creatinine concentration data from 6 healthy male volunteers with and without ingestion of 225 g boiled beef as an exogenous creatinine source. A model with firs
Autor:
Hua Zhang, Yifan Zhang, Xiao-yun Liu, Jing-Jing Bao, Liyan Miao, Zhendong Chen, Yong Jiang, Dafang Zhong, Jian Meng
Publikováno v:
Acta Pharmacol Sin
Furmonertinib was designed for the treatment of non-small cell lung cancer (NSCLC) patients with EGFR T790M mutation. In this study, we investigated the metabolic disposition and mass balance in humans and tissue distribution in rats. After a single